Systemic treatments for hepatocellular carcinoma: challenges and future perspectives
Sorafenib has been the only approved systemic treatment of hepatocellular carcinoma (HCC) for almost a decade. Recently, two new drugs showed positive results in two Phase III studies. The RESORCE trial identified regorafenib as a valid second-line treatment for patients progressing to sorafenib, th...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis
2018-01-01
|
| Series: | Hepatic Oncology |
| Subjects: | |
| Online Access: | https://www.futuremedicine.com/doi/10.2217/hep-2017-0020 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850152855659347968 |
|---|---|
| author | Francesco Tovoli Giulia Negrini Francesca Benevento Chiara Faggiano Elisabetta Goio Alessandro Granito |
| author_facet | Francesco Tovoli Giulia Negrini Francesca Benevento Chiara Faggiano Elisabetta Goio Alessandro Granito |
| author_sort | Francesco Tovoli |
| collection | DOAJ |
| description | Sorafenib has been the only approved systemic treatment of hepatocellular carcinoma (HCC) for almost a decade. Recently, two new drugs showed positive results in two Phase III studies. The RESORCE trial identified regorafenib as a valid second-line treatment for patients progressing to sorafenib, the REFLECT trial showed that lenvatinib is noninferior to sorafenib as front-line treatment. Following these trials, the therapeutic scenario will be dominated by anti-VEGFR drugs, with three different molecules showing a proven anticancer activity. Some open problems still remain and different immunotherapy trials are underway, following promising preliminary results. In this review we analyze: the most recent advancements about patients treated with sorafenib; the results of RESORCE and REFLECT trials; and the ongoing Phase III clinical trials. Finally, we discuss how they could address the current problems and possibly reshape the future of the systemic treatments for HCC. |
| format | Article |
| id | doaj-art-eae6ac9d6c1f48c99a31ef7ef1a9a0d0 |
| institution | OA Journals |
| issn | 2045-0923 2045-0931 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Taylor & Francis |
| record_format | Article |
| series | Hepatic Oncology |
| spelling | doaj-art-eae6ac9d6c1f48c99a31ef7ef1a9a0d02025-08-20T02:25:51ZengTaylor & FrancisHepatic Oncology2045-09232045-09312018-01-015110.2217/hep-2017-0020Systemic treatments for hepatocellular carcinoma: challenges and future perspectivesFrancesco Tovoli0Giulia Negrini1Francesca Benevento2Chiara Faggiano3Elisabetta Goio4Alessandro Granito51Department of Medical & Surgical Sciences, University of Bologna, S Orsola-Malpighi Hospital, Bologna, Italy1Department of Medical & Surgical Sciences, University of Bologna, S Orsola-Malpighi Hospital, Bologna, Italy1Department of Medical & Surgical Sciences, University of Bologna, S Orsola-Malpighi Hospital, Bologna, Italy1Department of Medical & Surgical Sciences, University of Bologna, S Orsola-Malpighi Hospital, Bologna, Italy1Department of Medical & Surgical Sciences, University of Bologna, S Orsola-Malpighi Hospital, Bologna, Italy1Department of Medical & Surgical Sciences, University of Bologna, S Orsola-Malpighi Hospital, Bologna, ItalySorafenib has been the only approved systemic treatment of hepatocellular carcinoma (HCC) for almost a decade. Recently, two new drugs showed positive results in two Phase III studies. The RESORCE trial identified regorafenib as a valid second-line treatment for patients progressing to sorafenib, the REFLECT trial showed that lenvatinib is noninferior to sorafenib as front-line treatment. Following these trials, the therapeutic scenario will be dominated by anti-VEGFR drugs, with three different molecules showing a proven anticancer activity. Some open problems still remain and different immunotherapy trials are underway, following promising preliminary results. In this review we analyze: the most recent advancements about patients treated with sorafenib; the results of RESORCE and REFLECT trials; and the ongoing Phase III clinical trials. Finally, we discuss how they could address the current problems and possibly reshape the future of the systemic treatments for HCC.https://www.futuremedicine.com/doi/10.2217/hep-2017-0020cabozantinibhepatocellular carcinomaimmunotherapylenvatinibmetronomic capecitabineregorafenib |
| spellingShingle | Francesco Tovoli Giulia Negrini Francesca Benevento Chiara Faggiano Elisabetta Goio Alessandro Granito Systemic treatments for hepatocellular carcinoma: challenges and future perspectives Hepatic Oncology cabozantinib hepatocellular carcinoma immunotherapy lenvatinib metronomic capecitabine regorafenib |
| title | Systemic treatments for hepatocellular carcinoma: challenges and future perspectives |
| title_full | Systemic treatments for hepatocellular carcinoma: challenges and future perspectives |
| title_fullStr | Systemic treatments for hepatocellular carcinoma: challenges and future perspectives |
| title_full_unstemmed | Systemic treatments for hepatocellular carcinoma: challenges and future perspectives |
| title_short | Systemic treatments for hepatocellular carcinoma: challenges and future perspectives |
| title_sort | systemic treatments for hepatocellular carcinoma challenges and future perspectives |
| topic | cabozantinib hepatocellular carcinoma immunotherapy lenvatinib metronomic capecitabine regorafenib |
| url | https://www.futuremedicine.com/doi/10.2217/hep-2017-0020 |
| work_keys_str_mv | AT francescotovoli systemictreatmentsforhepatocellularcarcinomachallengesandfutureperspectives AT giulianegrini systemictreatmentsforhepatocellularcarcinomachallengesandfutureperspectives AT francescabenevento systemictreatmentsforhepatocellularcarcinomachallengesandfutureperspectives AT chiarafaggiano systemictreatmentsforhepatocellularcarcinomachallengesandfutureperspectives AT elisabettagoio systemictreatmentsforhepatocellularcarcinomachallengesandfutureperspectives AT alessandrogranito systemictreatmentsforhepatocellularcarcinomachallengesandfutureperspectives |